Literature DB >> 2722585

Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas.

P W Grigsby1, J R Simpson, B N Emami, B B Fineberg, H G Schwartz.   

Abstract

Prognostic factors and results of therapy were analyzed in a retrospective examination of 121 patients with pituitary adenomas treated with surgery and postoperative irradiation (RT) from January 1954 through December 1982 at the Radiation Oncology Center, Mallinckrodt Institute of Radiology. The 10-year overall and disease-free survival for all patients was 85.1 and 89.4%. The expected survival for an age-, gender-, and race-matched population was not significantly distinct at 85.3% (p = 0.72). Follow-up of 94 surviving patients ranged from 3.4 to 29.5 years (mean, 11.7). Statistical analysis was performed for multiple prognostic factors including age, race, gender, disease bulk, visual field symptoms, disease type, surgical approach, and irradiation dose and volume. The only prognostic variable identified by univariate analysis to significantly alter disease-free survival was irradiation dose. Patients receiving 5000-5400 cGy had a tumor control rate of 94.1% (64/68) compared to 85.0% (17/20) for 4000-4999 cGy, 75.0% (18/24) for 3000-3999 cGy, and 28.6% (2/7) for less than 3000 cGy (p = 0.000059). Factors evaluated but established to be insignificant were age, race, gender, disease bulk, visual field symptoms, disease type, surgical approach, and irradiated volume. The 10-year disease-free survival by classification was 93.3% for patients with amenorrhea/galactorrhea, 89.9% for non-functioning adenomas, and 76.4% for acromegaly (p = 0.21). Overall improvement in visual field defects subsequent to treatment occurred in 48.4% (44/91) of those with visual field defects before RT and was significantly correlated with RT dose. The median time to progression of disease was 10.2 years with the last failure occurring at 25 years following the fulfillment of RT. Severe complications related to RT were apparent in 1.7% (2/121). None were known to have endured brain radionecrosis. Serious surgical complications occurred in 9.9% (12/121).

Entities:  

Mesh:

Year:  1989        PMID: 2722585     DOI: 10.1016/0360-3016(89)90942-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

2.  [Fractionated stereotactic-guided radiotherapy in the treatment of pituitary adenomas].

Authors:  Rosa M Cañón Rodríguez; David Ortiz de Urbina; Juan Carlos Viera; César Beltrán; Fernando Puebla; M Isabel García Berrocal; Ana Mañas; Carmen Peraza; Felipe A Calvo
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

3.  Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.

Authors:  M Brada; D Ford; S Ashley; J M Bliss; S Crowley; M Mason; B Rajan; D Traish
Journal:  BMJ       Date:  1992-05-23

4.  Postoperative radiation therapy for pituitary adenoma.

Authors:  K Isobe; M Ohta; S Yasuda'; T Uno; R Hara; N Machida; N Saeki; A Yamaura; N Shigematsu; H Ito
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

5.  Invasive adenoma and pituitary carcinoma: a SEER database analysis.

Authors:  Tara M Hansen; Sachin Batra; Michael Lim; Gary L Gallia; Peter C Burger; Roberto Salvatori; Gary Wand; Alfredo Quinones-Hinojosa; Lawrence Kleinberg; Kristin J Redmond
Journal:  Neurosurg Rev       Date:  2014-02-14       Impact factor: 3.042

Review 6.  Management of nonfunctioning pituitary tumors: radiotherapy.

Authors:  Giuseppe Minniti; John Flickinger; Barbara Tolu; Sergio Paolini
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 7.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

8.  Immunohistochemistry as a predictor of clinical outcome in patients given postoperative radiation for subtotally resected pituitary adenomas.

Authors:  J J Kovalic; G Mazoujian; D W McKeel; B B Fineberg; P W Grigsby
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

Review 9.  Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Enrico Clarke; Claudia Scaringi; Riccardo Maurizi Enrici
Journal:  Rep Pract Oncol Radiother       Date:  2014-10-14

10.  Radiologic follow-up of non-functioning pituitary adenomas: rationale and cost effectiveness.

Authors:  Ian C Coulter; Nitin Mukerji; Nicholas Bradey; Vincent Connolly; Philip J Kane
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.